Animal health company Zoetis (NYSE: ZTS) has been something of an investor darling since it was spun off from Pfizer in early 2013. Shares are up 382% since the close of the stock's first day of public trading about seven years ago.
Zoetis' popularity with growth investors is rooted in two important trends: the humanization of pet care and the increase in global demand for animal protein. These tailwinds have been propelling the growth of Zoetis' business and will continue to do so for years, but is the stock a good buy today?
Zoetis, a global leader in animal health, is on track to report over $6 billion in revenue for 2019 from its two segments, companion animal products and livestock.
Source Fool.com